# Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer

Source: https://onco.cc/trials/nct04725994/  
OnCo record `nct04725994` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IDX-1197+XELOX in gastric & gastro-oesophageal junction cancer, run by Idience Co., Ltd., active and no longer recruiting.

## Summary

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer is a phase 1/2 interventional study registered as NCT04725994 by Idience Co., Ltd., with 87 participants enrolled, started 2021-06-28 and due to reach its primary completion in 2026-07-31. Interventions recorded: IDX-1197+XELOX and IDX-1197+Irinotecan.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04725994
- Phase: 1/2
- Setting: An Open-Label, International, Multicenter, Phase 1b/2a Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX (Capecitabine and Oxaliplatin) or Irinotecan in Patients With Advanced Gastric Cancer
- Sponsor: Idience Co., Ltd.
- Enrolled: 87

## Sources

- ClinicalTrials.gov NCT04725994: https://clinicaltrials.gov/study/NCT04725994

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)

---
JSON: https://onco.cc/api/v1/entities/nct04725994.json